Benefits
NRF2 activation (master antioxidant response)
Sulforaphane is one of the most potent natural NRF2 activators identified — upregulating dozens of antioxidant and detoxification enzymes (glutathione, NQO1, HO-1, others) for 24+ hours per dose. Mechanism foundation distinguishing it from typical antioxidant supplements that don't induce endogenous antioxidant systems.
Cardiovascular and metabolic biomarkers
Clinical trials show sulforaphane improves cardiovascular biomarkers including blood pressure, oxidative stress markers, and possibly insulin sensitivity in adults with metabolic syndrome and type 2 diabetes. Effect sizes are modest but mechanistically meaningful.
Autism behavioral support
Multiple clinical trials in young men with autism spectrum disorder show sulforaphane (50-150 mg/day glucoraphanin equivalent) modestly improves social interaction and behavioral scores over 18 weeks. Effect sizes are clinically meaningful for a population with few well-evidenced treatment options.
Schizophrenia adjunct support
Emerging clinical evidence in schizophrenia shows sulforaphane as adjunct to antipsychotic therapy may modestly improve cognitive symptoms. Promising preliminary research aligned with the inflammation hypothesis of schizophrenia.
Detoxification enzyme support
Sulforaphane upregulates Phase II detoxification enzymes that support clearance of environmental toxins, pollutants, and pro-carcinogens. Mechanism foundation for the cancer prevention research and environmental health applications.
Cancer prevention research (preliminary)
Substantial preclinical and population research suggests cruciferous vegetable consumption is associated with reduced cancer risk. Human clinical trials of sulforaphane supplementation for cancer prevention are still emerging; promising but not definitively established.
Stability and bioavailability challenges
Sulforaphane is unstable — degrades rapidly in heat, light, and acid. Quality products provide either stabilized sulforaphane or glucoraphanin + active myrosinase enzyme for in-vivo conversion. Generic 'broccoli extract' without myrosinase may have minimal bioavailable sulforaphane despite labeled content.
Sourcing and form considerations
Broccoli sprouts naturally contain 10-100x more glucoraphanin than mature broccoli. Sprouts (1-2 oz daily) provide therapeutic doses; mature broccoli requires very high consumption. Supplements bypass the dietary intake limitation. Quality of myrosinase preservation matters significantly.
Mechanism of action
Nrf2-Keap1 pathway activation
Sulforaphane modifies cysteine residues on Keap1 (the Nrf2 repressor protein), preventing Keap1-mediated Nrf2 ubiquitination and proteasomal degradation. Free Nrf2 translocates to the nucleus and binds antioxidant response elements (AREs), inducing transcription of over 200 cytoprotective genes simultaneously.
Histone deacetylase (HDAC) inhibition
Sulforaphane inhibits class I and II histone deacetylases, maintaining chromatin in an open, transcription-accessible state at tumor suppressor gene loci. This epigenetic mechanism contributes to its cancer preventive effects independently of Nrf2 activation.
Phase II detoxification enzyme induction
Sulforaphane induces glutathione S-transferases (GSTs), NQO1 (NAD(P)H quinone oxidoreductase), and epoxide hydrolases that convert reactive carcinogen metabolites to water-soluble mercapturic acid conjugates for urinary excretion — providing systemic chemoprotection.
Clinical trials
Randomized, double-blind, placebo-controlled trial of sulforaphane (50–150 μmol/day from broccoli sprout extract) in 29 young men with moderate-to-severe ASD for 18 weeks.
29 young men with ASD aged 13–27. 18-week intervention.
Sulforaphane significantly improved social responsiveness (SRS: -34%), aberrant behavior (ABC: -17%), and social communication vs. placebo. Effects reversed upon discontinuation. No serious adverse events. Largest effect size of any compound in ASD clinical trials.
Clinical trial examining sulforaphane (concentrated broccoli sprout extract delivering ~150 μmol sulforaphane/day) in 97 patients with type 2 diabetes for 12 weeks.
97 T2DM patients. 12-week intervention.
Sulforaphane significantly reduced fasting blood glucose (significant in obese dysregulated subgroup) and HbA1c vs. placebo. Mechanism confirmed as NRF2-mediated suppression of glucose production enzymes in liver. Published in Science Translational Medicine.
Randomized, placebo-controlled trial of broccoli sprout beverage (delivering ~26–40 μmol sulforaphane/day) in 291 healthy adults in polluted Jiangsu province, China for 12 weeks.
291 healthy adults in heavily polluted region. 12-week intervention.
Broccoli sprout drink significantly increased urinary excretion of benzene (61%), acrolein (23%), and crotonaldehyde (23%) vs. placebo — demonstrating real-world protection against air pollution carcinogens.